Niu Jingxiu, Ren Yanjie, Zhang Tianyu, Yang Xuejing, Zhu Wei, Zhu Hui, Li Jing, Li Jiali, Pang Yan
Department of Oncology, Tianjin Union Medicine Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.
Shanghai Claison Biotechnology Co. Ltd., Shanghai, China.
Biomed Res Int. 2014;2014:214727. doi: 10.1155/2014/214727. Epub 2014 Aug 18.
This retrospective study determined the delayed-type hypersensitivity (DTH) skin test and safety of dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell immunotherapy and the survival compared to chemotherapy in 239 colorectal cancer (CRC) patients.
DTH and safety of the immunotherapy were recorded. The overall survival (OS) and disease free survival curves were compared according to the immunotherapy and/or chemotherapy received with Kaplan-Meier estimates.
Of the 70 patients who received immunotherapy, 62.86% had a positive DTH skin test, 38.57% developed fever, 47.14% developed insomnia, 38.57% developed anorexia, 4.29% developed joint soreness, and 11.43% developed skin rash. For 204 resectable CRC patients, median survival time (MST) (198.00 days) was significantly longer in patients with immunotherapy plus chemotherapy than with chemotherapy alone (106.00 days) (P = 0.02). For 35 patients with unresectable or postsurgery relapsed CRC and who were confirmed to be dead, no statistical difference was observed in the MST between the patients treated with immunotherapy and with chemotherapy (P = 0.41). MST in the patients treated with chemotherapy plus immunotherapy was 154 days longer than that of patients treated with chemotherapy alone (P = 0.41).
DC vaccination and CIK immunotherapy did not cause severe adverse effects, induce immune response against CRC, and prolong OS.
本回顾性研究确定了239例结直肠癌（CRC）患者中树突状细胞（DC）疫苗和细胞因子诱导的杀伤（CIK）细胞免疫疗法的迟发型超敏反应（DTH）皮肤试验、安全性以及与化疗相比的生存率。
记录免疫疗法的DTH和安全性。根据接受的免疫疗法和/或化疗，用Kaplan-Meier估计法比较总生存（OS）和无病生存曲线。
在接受免疫疗法的70例患者中，62.86%的患者DTH皮肤试验呈阳性，38.57%的患者出现发热，47.14%的患者出现失眠，38.57%的患者出现厌食，4.29%的患者出现关节酸痛，11.43%的患者出现皮疹。对于204例可切除的CRC患者，免疫疗法联合化疗患者的中位生存时间（MST）（198.00天）显著长于单纯化疗患者（106.00天）（P = 0.02）。对于35例不可切除或术后复发且已确认死亡的CRC患者，免疫疗法治疗组和化疗治疗组患者的MST无统计学差异（P = 0.41）。化疗联合免疫疗法治疗的患者的MST比单纯化疗患者长154天（P = 0.41）。
DC疫苗接种和CIK免疫疗法未引起严重不良反应，诱导了针对CRC的免疫反应，并延长了OS。
